OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
May 13, 2020
Through the agreement, Mylan will manufacture and distribute remdesivir in 127 low- and middle-income countries, including India.
In light of the current social distances measures, in place as a result of COVID-19, IMA Digital, part of IMA Group, has been providing virtual experiences for those interested in packaging and processing.
May 12, 2020
Some observers fear that political interference in the process may erode confidence in the scientific basis for FDA regulatory decisions.
The Coalition for Epidemic Preparedness Innovations will invest up to $384 million of additional funding, in addition to the $4 million it invested in March, to advance the clinical development of NVX-CoV2373, Novavax’s COVID-19 vaccine candidate.
The companies have entered into a partnership to produce hydroxychloroquine, a treatment currently under investigation for COVID-19.
May 08, 2020
The agency is responding to companies promoting and selling medical products that claim, but are unproven, to prevent or treat COVID-19.
May 07, 2020
A rolling review of data on the use of remdesivir, an investigational antiviral medicine, for the treatment of COVID-19 has been started by EMA’s Committee for Medicinal Products for Human Use.
A high-level meeting on COVID-19 policies, organized by EMA under the auspice of the International Coalition of Medicines Regulatory Authorities (ICMRA), has brought together global regulators to ensure a coordinated pandemic response.
May 06, 2020
Human cells form the source material for cell therapies and they require a variety of assays to detect bacterial, fungal, and viral contaminants.
Conventional cleaning methods can risk product loss of biologics, prompting biopharmaceutical manufacturers to seek alternative criteria to validate cleaning processes.